Greater physical and psychological symptom burden in patients with grade 3/4 chemotherapy-induced neutropenia

Supportive Cancer Therapy

Volumn 3, Issue 3, 2006, Pages 173-177

  Fortner, Barry V ^b   Houts, Arthur C ^a,b  

^a West Clinic ^*  (United States)

^b Accelerated Community Oncology Research Network   (United States)

Author keywords

Cancer Care Monitor; Myelosuppressive chemotherapy; Neutropenia Index

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PREDNISONE; VINCRISTINE;

ADULT; AGED; AGEUSIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HAIR LOSS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUTROPENIA; RETROSPECTIVE STUDY; SCORING SYSTEM; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33745785432     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.015     Document Type: Article

References (16)

1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323-1332.
2. Link BK, Budd GT, Scott S, et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 2001; 92:1354-1367.
3. Picozzi VJ, Pohlman BL, Morrison VA, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 2001; 15:1296-1306; discussion 310-1, 314.
4. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332:901-906.
5. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90:1205-1211.
6. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8:963-977.
7. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002; 62(suppl 1):65-78.
8. Padilla G, Ropka ME. Quality of life and chemotherapy-induced neutropenia. Cancer Nurs 2005; 28:167-171.
9. Calhoun EA, Chih-Hung C, Welshman EE, et al. A neutropenia-specific quality of life instrument: rationale for the development of the FACT-N. Proc Am Soc Clin Oncol 2002; 21:375a (Abstract #1498).
10. Fortner BV, Stolshek B, Schwartzberg L, et al. Decline in absolute neutrophil count (ANC) is associated with lower quality of life (QOL) in cancer patients receiving docetaxel. Proc Am Soc Clin Oncol 2002; 21:247b (Abstract #2808).
11. Okon TA, Fortner BV, Schwartzberg L, et al. Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Am Soc Clin Oncol 2002; 21:275b (Abstract #2920).
12. Glaspy J, Hackett J, Flyer P, et al. Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities. Blood 2001; 98:432a (Abstract #1812).
13. Martin M, Lluch A, Segui MA, et al. Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. Proc Am Soc Clin Oncol 2004; 23:32 (Abstract #620).
14. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): impact of adding prophylactic growth factors (GF) to TAC. GEICAM study 9803. Proc Am Soc Clin Oncol 2005; 24:29s (Abstract #604).
15. National Cancer Institute. Common Toxicity Criteria (CTC Version 2.0). Washington, DC; 2003.
16. Fortner B, Okon T, Schwartzberg L, et al. The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage 2003; 26:1077-1092.